- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01426906
Pharmacokinetic Drug Interaction Study in Healthy Male Subjects
A Randomized, Open-Label, Drug-Drug Interaction Study To Evaluate The Effect Of Ketoconazole Or Rifampicin On The Pharmacokinetic Characteristics And Safety Of Lc15-0444 In Healthy Male Volunteers
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This study is a randomized, open-label, 2-period, 3-treatment, 1-sequence, drug-drug interaction study in healthy volunteers to evaluate effect of ketoconazole or rifampicin on the PK characteristic and safety of LC15-0444.
Eligibility for participation of this study will be determined by demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 4 weeks(-28 d ~ -2 d) before the first drug administration(1 d). Eligible subjects will be randomized to one of study treatment groups.
According to the characteristics of anti-diabetic drugs, it is expected to be administered with other drugs in many patients. Therefore, Drug-Drug Interaction with CYP3A4 inducer and inhibitor should be identified in this trial.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Seoul, Korea, Republikken
- Asan Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Is a healthy male between 20 and 50 years old
- Has BMI result between 19 and 26 kg/m2 at screening; and a total body weight over 55 kg. BMI(kg/m2) = body weight(kg)/{height(m)}2.
- Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
- Agrees to use an adequate means of contraception during clinical trials
Exclusion Criteria:
- Subjects with evidence or history of clinically significant hepatic, renal, digestive, neurologic, pulmonary, musculoskeletal, endocrine, hematological, cardiovascular or psychiatric disease
- Subjects with evidence or history of gastrointestinal disease or surgery possibly affecting drug absorption.
- Subjects with history of hypersensitivities or clinically significant adverse events caused by DPPIV inhibitors, ketoconazole, rifampicin, and other drugs
- Subjects who have donated a unit of blood within 60 days or blood components within 30 days before the first administration of the investigational product.
- Subjects who consume excessive alcohol or caffeine; who excessively smoke
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Study A
|
Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
|
Eksperimentel: Study B
|
Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Cmax
Tidsramme: Until Day 18 or 20
|
Until Day 18 or 20
|
AUC(last)
Tidsramme: Until Day 18 or 20
|
Until Day 18 or 20
|
AUC(0-24hr)
Tidsramme: Until Day 18 or 20
|
Until Day 18 or 20
|
Tmax
Tidsramme: Until Day 18 or 20
|
Until Day 18 or 20
|
t(1/2beta)
Tidsramme: Until Day 18 or 20
|
Until Day 18 or 20
|
(6-b-hydrocortisol)/(cortisol) ratio
Tidsramme: Until Day 20
|
Until Day 20
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Lægemidlers fysiologiske virkninger
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Hormoner, hormonsubstitutter og hormonantagonister
- Antibakterielle midler
- Cytokrom P-450 CYP3A-hæmmere
- Cytokrom P-450 enzymhæmmere
- Leprostatiske midler
- Hormonantagonister
- Cytokrom P-450 enzyminducere
- Antifungale midler
- Steroidsyntesehæmmere
- Cytokrom P-450 CYP3A inducere
- Antituberkulære midler
- 14-alfa-demethylasehæmmere
- Antibiotika, Antituberkulær
- Cytokrom P-450 CYP2B6 inducere
- Cytokrom P-450 CYP2C8 inducere
- Cytokrom P-450 CYP2C19 inducere
- Cytokrom P-450 CYP2C9 inducere
- Ketoconazol
- Rifampin
Andre undersøgelses-id-numre
- LG-DPCL007
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Sunde mandlige frivillige
-
Icahn School of Medicine at Mount SinaiNational Institute on Deafness and Other Communication Disorders (NIDCD)AfsluttetMal de Debarquement Syndrome (MdDS)Forenede Stater
-
Icahn School of Medicine at Mount SinaiNew York University; National Institute on Deafness and Other Communication... og andre samarbejdspartnereRekruttering
-
University of MinnesotaAfsluttetMal de Debarquement syndromForenede Stater
-
Mostafa BahaaSahar El-Haggar, Prof Clinical pharmacy Department- Tanta University; Principal... og andre samarbejdspartnereRekruttering
-
University of MinnesotaTrukket tilbageMal de Debarquement syndrom
-
University of MinnesotaTrukket tilbageMal de Debarquement syndromForenede Stater
-
Banaras Hindu UniversityInstitute of Medical Sciences of the Banaras Hindu University (BHU),IndiaAfsluttetGrand Mal Status Epilepticus
-
Hospital Universitari de BellvitgeHospital Clinic of Barcelona; Institut d'Investigació Biomèdica de Girona... og andre samarbejdspartnereAfsluttetGrand Mal Status Epilepticus | Ikke-konvulsiv Status EpilepticusSpanien
-
Children's Hospital Medical Center, CincinnatiNational Institute of Neurological Disorders and Stroke (NINDS)AfsluttetEpilepsi | Anfald | Fravær i barndommen Epilepsi | Petit Mal EpilepsiForenede Stater
Kliniske forsøg med Ketoconazole
-
NYU Langone HealthNational Cancer Institute (NCI)Afsluttet
-
Chong Kun Dang PharmaceuticalSeverance HospitalAfsluttetType 2 diabetes mellitusKorea, Republikken
-
University of PecsHungarian Ministry of Innovation and Technology; HECRIN ConsortiumAfsluttet
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)AfsluttetBlærekræft | Overgangscellekræft i nyrebækkenet og urinlederenForenede Stater
-
St. Louis UniversityAfsluttetSeborrheisk dermatitisForenede Stater
-
PfizerAfsluttet
-
Taro Pharmaceuticals USAAfsluttetTinea VersicolorForenede Stater
-
Eisai Inc.Afsluttet
-
Encube Ethicals Pvt. Ltd.Novum Pharmaceutical Research Services; ACM Global LaboratoriesAfsluttetTinea PedisForenede Stater, Belize, Sankt Lucia
-
Galderma R&DAfsluttetSeborrheic dermatitis i hovedbundenBelgien, Frankrig, Tyskland, Korea, Republikken, Mexico